Sirukumab
As of the edition of 20 October 2026, Sirukumab is an antibody: stopped in 2021; acts on IL6.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 16, 3 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Lungs and airways; Heart and blood vessels; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Sirukumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL6 | Interleukin-6 | P05231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 5 | 4 | 0 | 1 |
| Phase 3 | 7 | 5 | 0 | 2 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Lead sponsor of trials | 2007 to now |
| GSK | Lead sponsor of trials | 2015 to now |